Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rossari BiotechNSE:ROSSARI +1.13%85 EV-to-EBITDA is 9.55 as of Aug. 16, 2026, which is 48% below its 10-year median of 18.54. GuruFocus rates NSE:ROSSARI with a GF Score™ of 85/100 and a GF Value™ of ₹921.79 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,330 Chemicals companies, Rossari Biotech ranks better than 63.08% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Rossari Biotech's enterprise value is ₹31,035 Mil.
Rossari Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹3,249 Mil. Therefore, Rossari Biotech's EV-to-EBITDA for today is 9.55.
The historical rank and industry rank for Rossari Biotech's EV-to-EBITDA or its related term are showing as below:
NSE:ROSSARI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.77 Med: 18.54 Max: 54.89
Current: 9.55
During the past 9 years, the highest EV-to-EBITDA of Rossari Biotech was 54.89. The lowest was 7.77. And the median was 18.54.
NSE:ROSSARI's EV-to-EBITDA is ranked better than 63.08% of 1330
companies
in the Chemicals industry
Industry Median: 13.265
vs NSE:ROSSARI: 9.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rossari Biotech's PE Ratio (TTM) for today is calculated as:
Rossari Biotech's share price for today is ₹503.00.
Rossari Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Rossari Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ROSSARI vs LIN, SHW, ECL: EV-to-EBITDA Comparison
For the Specialty Chemicals subindustry, Rossari Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rossari Biotech EV-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Rossari Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rossari Biotech's EV-to-EBITDA falls into.
Rossari Biotech's current Enterprise Value is ₹31,035 Mil.
Rossari Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,249 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rossari Biotech (NSE:ROSSARI) has a EV-to-EBITDA of 9.55 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Rossari Biotech. This is 48% below median its historical median of 18.54. Over the past decade, Rossari Biotech's EV-to-EBITDA has ranged from 7.77 to 54.89. According to the industry distribution chart, Rossari Biotech ranks #491 out of 1330 companies in the Chemicals industry, placing it in the top 36.9%.
Is Rossari Biotech's EV-to-EBITDA too high?
Rossari Biotech's current EV-to-EBITDA of 9.55 is 48% below median its 10-year median of 18.54. Over the past 10 years, this metric has ranged from a low of 7.77 to a high of 54.89. The Chemicals industry median EV-to-EBITDA is 13.27. Rossari Biotech's value of 9.55 is 28% below this industry median. Based on the distribution chart, Rossari Biotech ranks #491 out of 1330 companies in the Chemicals industry, which is above the industry midpoint. Overall, Rossari Biotech has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rossari Biotech's EV-to-EBITDA compare to LIN and SHW?
According to the Chemicals industry distribution chart, Rossari Biotech ranks #491 out of 1330 companies for EV-to-EBITDA. This puts Rossari Biotech in the upper half of its industry. The industry median EV-to-EBITDA is 13.27. Rossari Biotech's value of 9.55 is 28% below this benchmark. Historically, Rossari Biotech's own EV-to-EBITDA has ranged from 7.77 to 54.89 over the past decade. While the company's 10-year median is 18.54 vs. the industry median of 13.27, Rossari Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Chemicals company?
The median EV-to-EBITDA among Chemicals companies is 13.27, based on 1,330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rossari Biotech's current EV-to-EBITDA of 9.55 is 28% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Rossari Biotech. For the Chemicals industry, the median EV-to-EBITDA is 13.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rossari Biotech's current EV-to-EBITDA is 9.55, which is 48% below median its own 10-year median of 18.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rossari Biotech stock overvalued right now?
Based on GuruFocus' analysis, Rossari Biotech (NSE:ROSSARI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹921.79, compared to a current price of ₹503.00 — trading 45.4% below its estimated fair value. The current EV-to-EBITDA is 9.55, which is 48% below median its 10-year median of 18.54 and 28% below the Chemicals industry median of 13.27. Rossari Biotech's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Rossari Biotech (NSE:ROSSARI), the current EV-to-EBITDA is 9.55 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rossari Biotech (NSE:ROSSARI) Overvalued in 2026?
Based on GuruFocus' analysis, Rossari Biotech stock appears to be undervalued.
The current stock price of ₹503.00 is trading 45.4% below its estimated GF Value™ of ₹921.79.
GuruFocus considers Rossari Biotech to be Possible Value Trap.
Key valuation signals for NSE:ROSSARI:
EV-to-EBITDA: 9.55 (48% below median its 10-year median of 18.54)
GF Value™: ₹921.79 vs. price of ₹503.00 (45.4% below fair value)
Industry Position: 28% below the Chemicals median (#491 of 1330)
No single metric tells the full story. See the NSE:ROSSARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rossari Biotech Ltd is a specialty chemical manufacturing company. It provides customized solutions to specific industrial and production requirements of its customers in the FMCG, apparel, poultry, and animal feed industries through its product portfolio comprising home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its business is organized into three categories: home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its products include soaps and detergents, paints, inks and coatings, ceramics and tiles, water treatment chemicals, pulp and paper, and cleaning chemical formulations, among others. The company generates the majority revenue from India.
85GF Score
Get the complete analysis for NSE:ROSSARI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ROSSARI has been successfully added to your 
